APC resistance during the normal menstrual cycle

Thrombosis and Haemostasis

Volumn 98, Issue 6, 2007, Pages 1246-1251

  van Rooijen, Marianne ^a   Silveira, Angela ^a   Thomassen, Stella ^b   Odeberg, Jacob ^a   Hamsten, Anders ^a   Rosing, Jan ^b   Bremme, Katarina ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

APC resistance; aPTT based; Estradiol; ETP based; Menstrual cycle

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; ESTRADIOL; ESTROGEN; PROGESTERONE; THROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; GENE MUTATION; HETEROZYGOTE; HORMONE RESPONSE; HUMAN; LUTEAL PHASE; MENSTRUAL CYCLE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ESTRADIOL; FACTOR V; FEMALE; HUMANS; MENSTRUAL CYCLE; PARTIAL THROMBOPLASTIN TIME; PROGESTERONE; PROSPECTIVE STUDIES; THROMBIN; TIME FACTORS; UP-REGULATION;

EID: 36949004771     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-02-0139     Document Type: Article

References (37)

1. Martinelli I. Thromboembolism in women. Semin Thromb Hemost 2006; 32: 709-715.
2. Bottiger LE, Boman G, Eklund G, et al. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980; 110:97-101.
3. Koster T, Rosendahl FR, de Ronde et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-1506.
4. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522.
5. Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005; 94: 17-25.
6. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
7. Lunghi B, Iacoviello L, Gemmati D, et al. Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost 1996; 75: 45-48.
8. Chan WP, Lee CK, Kwong YL, et al. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998; 91: 1135-1139.
9. Williamson D, Brown K, Luddington R, et al. Factor V Cambridge: a new mutation (Arg306-Thr) associated with resistance to activated protein C. Blood 1998; 91: 1140-1144.
10. Curvers J, Thomassen MC, Nicolaes GA, et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol 1999; 105: 88-94.
11. Rosing J, Curvers J, Tans G. Oral contraceptives, thrombosis and haemostasis. Eur J Obstet Gynecol Reprod Biol 2001; 95: 193-197.
12. Couturaud F, Kearon C, Leroyer C, et al.; Groupe d'Etude de la Thrombose de Bretagne Occidentale (G.E.T.B.O). Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. Thromb Haemost 2006; 96: 744-749.
13. Curvers J, Thomassen MC, Rimmer J, et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 2002; 88: 5-11.
14. Rosing J, Middeldorp S, Curvers J, et al.Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-2040.
15. van Rooijen M, Silveira A, Hamsten A, et al. Sex hormone - binding globulin - a surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol 2004; 190: 332-337.
16. Tans G, van Hylckama Vlieg A, Thomassen MC, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003; 122: 465-470.
17. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-1593.
18. World Health Organization. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-1593.
19. Alhenc-Gelas M, Plu-Bureau G, Guillonneau. S, et al. Impact of progestagens on activated protein C (APC) resistance among users of of oral contraceptives. J Thromb Haemost 2004; 2: 1594-2600.
20. Leiden mutation: a randomized trial. Blood 2004; 103: 927-933.
21. Wramsby ML, Bokarewa MI, Blomback M, et al. Response to activated protein C during normal menstrual cycle and ovarian stimulation. Hum Reprod 2000; 15: 795-797.
22. Wramsby ML, Bremme K, Blomback M. Measurement of activated protein C resistance during menstrual cycle in women with and without the Leiden mutation. Thromb Haemost 2001; 85: 614-618.
23. de Visser MC, van Hylckama Vlieg A, Tans G, et al. Determinants of the APTT- and ETP-based APC sensitivity tests. J Thromb Haemost 2005; 3: 1488-1494.
24. Nicolaes GA, Thomassen MC, Tans G, et al. Effect of activated protein C on thrombin generation and on the thrombin potential in normal and APC-resistant individuals. Blood Coagul Fibrinolysis 1997; 8: 28-38.
25. Holmberg K, Persson ML, Uhlen M, et al. Pyrosequencing analysis of thrombosis-associated risk markers. Clin Chem 2005; 51: 1549-1552.
26. Roger EK. Experimental design: Procedures for the behavioral sciences. Brooks/Cole Publishing Company Pacific Grove, USA 1995.
27. Littell RC, Milliken GA, Stroup WW, et al. SAS System for Mixed Models, Cary, NC: SAS Institute Inc., 1996.
28. de Visser MC, Roosendaal FR, Bertina RM. A reduced sensitivity for protein C in the absence for Factor V increases the risk of venous thrombosis. Blood 1998; 93: 1271-1276.
29. Zoller B, Hillarp A, Berntorp E, et al. Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. Annu Rev Med 1997; 48: 45-58.
30. Meinardi JR, Henkens CM, Heringa MP, et al. Acquired APC resistance related to oral contraceptives and pregnancy and its possible implications for clinical practice. Blood Coagul Fibrinolysis 1997; 8: 152-154.
31. Hoibraaten E, Mowinckel MC, de Ronde H, et al. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 2001; 115: 415-420.
32. Olivieri O, Friso S, Manzato F, et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 465-470.
33. Lindberg BS, Johansson ED, Nilsson BA. Plasma levels of nonconjugated oestrone, oestradiol-17beta and oestriol during uncomplicated pregnancy. Acta Obstet Gynecol Scand Suppl 1974; 32: 21-36.
34. Bokarewa MI, Wramsby M, Bremme K, et al. Variability of the response to activated protein C during normal pregnancy. Blood Coagul Fibrinolysis 1997; 8: 239-244.
35. Cumming AM, Tait RC, Fildes S, et al. Diagnosis of APC Resistance during pregnancy. Br J Haematol 1996; 92: 1026-1029.
36. Curvers J, Nap AW, Thomassen MC, et al. Effect of in vitro fertilization treatment and subsequent pregnancy on the protein C pathway. Br J Haematol 2001; 115: 400-407.
37. van Rooijen M, Silveira A, Thomassen S, et al. Rapid activation of haemostasis after hormonal emergency contraception. Thromb Haemost 2007; 97: 15-20.